CRSP CRISPR Therapeutics AG - Common Shares
NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗ बंद अक्ट 2, 2026 10-K/10-Q अग 3, 2026
$55.43
· 52 सप्ताह की सीमा का %
· निम्न से ऊपर
· उच्च तक
$44.1252w निम्न
$78.4852w उच्च
मार्केट कैप (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
राजस्व (TTM)
$13M
आपके बैज
52W रेंज
$44–$78
विश्लेषक रेटिंग
BUY
मूल्य लक्ष्य
$88
P/E
-11.8
ROE
-26.1%
शुद्ध लाभ मार्जिन
-3368.7%
आपकी बैज स्ट्रिप खाली है — इस पेज पर कहीं भी एक मीट्रिक पिन करें।
CRSP स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$55.43
मार्केट कैप (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
राजस्व (TTM)
$13M
ROE (TTM)
-26.1%
52W रेंज
$44–$78
CRSP स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
सीमा
बार
बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।
CRISPR Therapeutics AG - Common Shares के बारे में विकिपीडिया से कंपनी का अवलोकन
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
क्षेत्रHealthcare
उद्योगBiotechnology
देशCH
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व$4M2016-12-31 → 2025-12-31
EPS$-6.472017-12-31 → 2025-12-31
फ्री कैश फ्लो$-346M2016-12-31 → 2025-12-31
शुद्ध मार्जिन-3368.7%2016-12-31 → 2025-12-31
मूल्यांकन और अनुपात
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
| मेट्रिक | 5Y रुझान | CRSP | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| P/E (TTM) | -11.85Y औसत ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 400.15Y औसत ≈841.4 | ≈841.4 | · | · | |
| P/B (MRQ) | 3.15Y औसत ≈2.2 | ≈2.2 | · | · | |
| मूल्य / FCF (TTM) | -14.45Y औसत ≈-9.9 | ≈-9.9 | · | · | |
| मूल्य / नकदी प्रवाह (TTM) | -14.55Y औसत ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book (मूल्य / मूर्त पुस्तक) | 2.85Y औसत ≈2.2 | ≈2.2 | · | · |
सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
| मेट्रिक | 5Y रुझान | CRSP | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| परिचालन मार्जिन (TTM) | -3990.0%5Y औसत ≈-15278.7% | ≈-15278.7% | · | · | |
| EBITDA मार्जिन (TTM) | -3850.4%5Y औसत ≈-14752.4% | ≈-14752.4% | · | · | |
| प्रीटैक्स मार्जिन (TTM) | -3346.1%5Y औसत ≈-14347.2% | ≈-14347.2% | · | · | |
| शुद्ध लाभ मार्जिन (TTM) | -3368.7%5Y औसत ≈-14364.6% | ≈-14364.6% | · | · | |
| ROA (TTM) | -19.3%5Y औसत ≈-11.7% | ≈-11.7% | -40.4% | शीर्ष स्तर | |
| ROE (TTM) | -26.1%5Y औसत ≈-15.6% | ≈-15.6% | -46.3% | शीर्ष स्तर | |
| ROIC | -34.8%5Y औसत ≈-18.3% | ≈-18.3% | -57.7% | शीर्ष स्तर |
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
| मेट्रिक | 5Y रुझान | CRSP | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| वर्तमान अनुपात (MRQ) | 17.85Y औसत ≈17.7 | ≈17.7 | 7.8 | मजबूत तरलता | |
| Quick Ratio (त्वरित अनुपात) | 13.25Y औसत ≈17.5 | ≈17.5 | 6.5 | मजबूत तरलता |
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
| मेट्रिक | 5Y रुझान | CRSP | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Revenue YoY (राजस्व YoY) | -90.6%5Y औसत ≈31552.0% | ≈31552.0% | · | · | |
| Revenue CAGR 3Y (राजस्व CAGR 3Y) | 43.1%5Y औसत ≈226.6% | ≈226.6% | · | · | |
| Revenue CAGR 5Y (राजस्व CAGR 5Y) | 37.3% | · | · | · |
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
| मेट्रिक | 5Y रुझान | CRSP | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Asset Turnover (परिसंपत्ति टर्नओवर) | 0.05Y औसत ≈0.1 | ≈0.1 | · | · | |
| Receivables Turnover (प्राप्य टर्नओवर) | 0.35Y औसत ≈817.5 | ≈817.5 | · | · |
मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
0.09%
अगली रिपोर्ट
नव 09, 2026
| Period | रिपोर्ट | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|---|
| 30 जून 2026 | अग 10, 2026 | $-0.94 | $-1.22 | 23.0% |
| 31 मार्च 2026 | $-1.28 | $-1.25 | -2.5% | |
| 31 दिसमबर 2025 | $-1.37 | $-1.18 | -16.4% | |
| 30 सितमबर 2025 | $-1.17 | $-1.29 | 9.0% | |
| 30 जून 2025 | $-1.29 | $-1.45 | 11.2% | |
| 31 मार्च 2025 | $-1.58 | $-1.28 | -23.9% |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
बैलेंस शीट
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
नकदी प्रवाह
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
लाभप्रदता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
दक्षता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
प्रति शेयर
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.04 | $22.53 | $23.52 | $23.89 | $31.17 | $22.52 | $15.46 | $7.56 | $4.63 | $5.86 | · | |
| Revenue / Share | $0.04 | $0.44 | $4.69 | $0.02 | $11.38 | $0.01 | $5.09 | · | · | · | · | |
| Cash Flow / Share | $-3.84 | $-1.69 | $-3.29 | $-6.38 | $6.70 | $-3.61 | $1.00 | · | · | · | · | |
| Cash / Share | $3.62 | $3.48 | $4.87 | $2.70 | $11.99 | $15.81 | $15.53 | $8.81 | $5.91 | $7.94 | · | |
| EPS (TTM) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-7.05 | · |
विकास दरें
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
आय विवरण
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
बैलेंस शीट
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
नकदी प्रवाह
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
लाभप्रदता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
दक्षता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
प्रति शेयर
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.07 | $18.83 | · | $20.41 | $19.36 | $21.18 | · | $22.73 | $23.29 | $24.56 | · | $21.75 | $22.88 | $23.52 | · | $24.97 | |
| Revenue / Share | $0.11 | $0.02 | · | $0.01 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.00 | $0.89 | $1.27 | · | $0.00 | |
| Cash Flow / Share | · | $-1.13 | · | · | · | $-0.63 | · | · | · | $1.34 | · | · | · | $0.11 | · | · | |
| Cash / Share | $3.01 | $4.39 | · | $3.05 | $2.19 | $2.72 | · | $2.64 | $5.70 | $8.34 | · | $6.64 | $5.60 | $4.37 | · | $6.32 | |
| EPS (TTM) | $-4.71 | $-6.17 | · | $-5.56 | $-5.40 | $-4.49 | · | $-2.81 | $-3.21 | $-2.70 | · | $-4.46 | $-5.29 | $-6.71 | · | $-8.52 |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $38M | $38M | $38M | · | $203M | $202M | $272M | · | $170M | $170M | $100M | · | $14M | |
| Net Income TTM | $-451M | $-569M | · | $-488M | $-468M | $-386M | · | $-240M | $-266M | $-217M | · | $-354M | $-416M | $-524M | · | $-681M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -11.6 | -7.7 | · | -11.7 | -9.0 | -7.6 | · | -16.7 | -16.8 | -25.2 | · | -10.2 | -10.6 | -6.7 | · | -7.7 | |
| P/S | 393.7 | 1117.5 | · | 158.7 | 113.0 | 78.0 | · | 19.8 | 22.7 | 21.3 | · | 21.2 | 26.2 | 35.6 | · | 362.9 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| Earnings Yield | -8.6% | -13.0% | · | -8.6% | -11.1% | -13.2% | · | -6.0% | -5.9% | -4.0% | · | -9.8% | -9.4% | -14.8% | · | -13.0% |
सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| राजस्व | $4M | $37M | $371M | $1M | $915M |
| परिचालन मार्जिन % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| शुद्ध आय | $-582M | $-366M | $-154M | $-650M | $378M |
| तनुकरणित EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| त्वरित अनुपात | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-346M | $-145M | $-270M | $-533M | $457M |
संस्थागत मालिक (13F) 572 फाइलर्स · $4.3B कुल · तिथि अनुसार 30 सितमबर 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
धारक
572
धारित मूल्य
$4.3B
नई स्थितियाँ
82
बाहर निकली पोजीशन
47
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 82 (-14 पिछली तिमाही की तुलना में) | 47 (-13 पिछली तिमाही की तुलना में) | 158 (-19 पिछली तिमाही की तुलना में) | 157 (+29 पिछली तिमाही की तुलना में) | -2.0M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| ARK Investment Management LLC | $515999631 | 9460939 | 12.01% | शेयर |
| BlackRock, Inc. | $455353197 | 8348977 | 10.60% | शेयर |
| Orbis Allan Gray Ltd | $297197241 | 5449161 | 6.92% | शेयर |
| Capital World Investors | $259039094 | 4749525 | 6.03% | शेयर |
| STATE STREET CORP | $235703664 | 4321666 | 5.49% | शेयर |
| GSK plc | $175652997 | 3220627 | 4.09% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $136919043 | 2509915 | 3.19% | शेयर |
| VANGUARD GROUP INC | $118954581 | 2268394 | 2.77% | शेयर |
| SR One Capital Management, LP | $111194134 | 2038763 | 2.59% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $108459389 | 1988621 | 2.53% | शेयर |
| FMR LLC | $104089735 | 1908503 | 2.42% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $93848832 | 1720734 | 2.19% | शेयर |
| Amova Asset Management Americas, Inc. | $93762487 | 1720097 | 2.18% | शेयर |
| EcoR1 Capital, LLC | $75771113 | 1389276 | 1.76% | शेयर |
| UBS Group AG | $71856395 | 1317499 | 1.67% | शेयर |
| Capital International Investors | $69178918 | 1268407 | 1.61% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $64457935 | 1181847 | 1.50% | शेयर |
| BANK OF AMERICA CORP /DE/ | $62999405 | 1155105 | 1.47% | शेयर |
| NEA Management Company, LLC | $57734408 | 1058570 | 1.34% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57694430 | 1057837 | 1.34% | शेयर |
| D. E. Shaw & Co., Inc. | $48748506 | 893812 | 1.13% | शेयर |
| MORGAN STANLEY | $47992455 | 879949 | 1.12% | शेयर |
| NORTHERN TRUST CORP | $47072983 | 863091 | 1.10% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35380807 | 648713 | 0.82% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $31089982 | 570040 | 0.72% | शेयर |
| CITADEL ADVISORS LLC | $25404514 | 465796 | 0.59% | शेयर |
| JPMORGAN CHASE & CO | $24569275 | 431669 | 0.57% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23298288 | 427178 | 0.54% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $20836025 | 382032 | 0.49% | शेयर |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20833789 | 381991 | 0.49% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18456336 | 338400 | 0.43% | पुट ऑप्शन |
| Bank of New York Mellon Corp | $17821531 | 326761 | 0.41% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17763678 | 325700 | 0.41% | कॉल ऑप्शन |
| Logos Global Management LP | $16362000 | 300000 | 0.38% | शेयर |
| CITADEL ADVISORS LLC | $15822054 | 290100 | 0.37% | पुट ऑप्शन |
| Squarepoint Ops LLC | $15641472 | 286789 | 0.36% | शेयर |
| Jump Financial, LLC | $15159502 | 277952 | 0.35% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $15034803 | 275375 | 0.35% | शेयर |
| GOLDMAN SACHS GROUP INC | $14855182 | 272372 | 0.35% | शेयर |
| NORGES BANK | $14767032 | 270756 | 0.34% | शेयर |
| WELLS FARGO & COMPANY/MN | $14353246 | 263169 | 0.33% | शेयर |
| CITADEL ADVISORS LLC | $13973148 | 256200 | 0.33% | कॉल ऑप्शन |
| AMERIPRISE FINANCIAL INC | $13669977 | 250614 | 0.32% | शेयर |
| Vestmark Advisory Solutions, Inc. | $13213188 | 242266 | 0.31% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $12652626 | 231988 | 0.29% | शेयर |
| JANE STREET GROUP, LLC | $12566016 | 230400 | 0.29% | कॉल ऑप्शन |
| PEAK6 LLC | $11633382 | 213300 | 0.27% | पुट ऑप्शन |
| Nuveen, LLC | $11076474 | 203089 | 0.26% | शेयर |
| ROYAL BANK OF CANADA | $9438000 | 173045 | 0.22% | शेयर |
| Marex Group Ltd | $9303652 | 170584 | 0.22% | शेयर |
कार्यकर्ता और 5%+ मालिक 6 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 फाइलिंग | 16 फ़रवरी 2021 | · | प्रारंभिक फाइलिंग | · | SEC |
| GlaxoSmithKline plc ×5 फाइलिंग | 10 जुलाई 2020 | · | प्रारंभिक फाइलिंग | · | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 फाइलिंग | 4 फ़रवरी 2020 | · | प्रारंभिक फाइलिंग | · | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 फाइलिंग | 7 जून 2019 | · | प्रारंभिक फाइलिंग | · | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 फाइलिंग | 8 फ़रवरी 2018 | · | प्रारंभिक फाइलिंग | · | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 फाइलिंग | 16 जनवरी 2018 | · | प्रारंभिक फाइलिंग | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
कंपनी के अंदरूनी सूत्र 32 इनसाइडर्स · 12 अधिकारी · 16 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 मार्च 2026 M | 255501 | 0 | 9 | $-10756932 |
| Brendan Smith | Chief Financial Officer | 18 फ़रवरी 2023 M | 5072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 मार्च 2021 M | 1891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 मार्च 2025 M | 10544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 अगस्त 2022 A | 26797 | 0 | 0 | $0 |
| James R. Kasinger | General Counsel and Secretary | 22 सितमबर 2026 M | 94784 | 0 | 6 | $-1272398 |
| Naimish Patel | Chief Medical Officer | 29 मई 2026 A | 19357 | 1 | 2 | $-312892 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 अक्टूबर 2023 A | 4411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 दिसमबर 2021 M | 52364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 जनवरी 2018 M | 25204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 जून 2017 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 अक्टूबर 2016 C | 505617 | 0 | 0 | $0 |
| Ali Behbahani | निदेशक | 17 सितमबर 2026 M | 16637 | 0 | 1 | $-780934 |
| Christian Rommel | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| Harold Edward Fleming | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| Douglas A Treco | निदेशक | 5 जून 2026 A | 22000 | 0 | 0 | $0 |
| Briggs Morrison | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| Katherine A High | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| John Greene | निदेशक | 5 जून 2026 A | 7000 | 0 | 0 | $0 |
| Simeon George | निदेशक | 5 जून 2026 A | 1730179 | 0 | 0 | $0 |
| Maria Fardis | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| Sandesh Mahatme | निदेशक | 5 जून 2026 A | · | 0 | 0 | $0 |
| Bradley J Bolzon PhD | निदेशक | 9 जून 2022 A | 148831 | 0 | 0 | $0 |
| Pablo J Cagnoni | निदेशक | 19 नवमबर 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | निदेशक | 18 दिसमबर 2018 S | 1171268 | 0 | 0 | $0 |
| Thomas Woiwode | निदेशक | 15 जून 2018 A | 640014 | 0 | 0 | $0 |
| Anthony N Coles | निदेशक | 31 मई 2017 A | 70000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% मालिक | 4 दिसमबर 2017 S | 3722534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% मालिक | 24 अक्टूबर 2016 C | 744380 | 0 | 0 | $0 |
| GSK plc | 10% मालिक | 24 अक्टूबर 2016 C | 3220627 | 0 | 0 | $0 |
| Raju Prasad | · | 7 अगस्त 2026 G | 14815 | 0 | 10 | $-5100841 |
| Rodger Novak | · | 30 जून 2021 S | 573007 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
ईटीएफ स्वामित्व 27 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.53% | 22018 NS | 31 जुलाई 2026 | N-PORT |
| IDNA · iShares Trust | 1.46% | 71206 SH | 11 सितमबर 2026 | दैनिक |
| LABU · Direxion Shares ETF Trust | 0.66% | 68253 NS | 31 जुलाई 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.36% | 6830 SH | 2 अक्टूबर 2026 | दैनिक |
| IBB · iShares Trust | 0.35% | 685566 SH | 11 सितमबर 2026 | दैनिक |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70696 SH | 19 अगस्त 2026 | दैनिक |
| IWM · iShares Trust | 0.16% | 2381008 SH | 11 सितमबर 2026 | दैनिक |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536446 SH | 19 अगस्त 2026 | दैनिक |
| RSSL · Global X Funds | 0.14% | 44639 NS | 31 जुलाई 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.11% | 6887 SH | 2 अक्टूबर 2026 | दैनिक |
| ESML · iShares Trust | 0.06% | 34534 SH | 11 सितमबर 2026 | दैनिक |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1106455 SH | 19 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | 0.04% | 5543 SH | 11 सितमबर 2026 | दैनिक |
| IWO · iShares Trust | 0.04% | 115267 SH | 11 सितमबर 2026 | दैनिक |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13170 SH | 19 अगस्त 2026 | दैनिक |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.04% | 1727 SH | 2 अक्टूबर 2026 | दैनिक |
| XT · iShares Trust | 0.03% | 21859 SH | 11 सितमबर 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7774 SH | 19 अगस्त 2026 | दैनिक |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20627 SH | 19 अगस्त 2026 | दैनिक |
| IYY · iShares Trust | 0.01% | 4231 SH | 11 सितमबर 2026 | दैनिक |
| ITOT · iShares Trust | 0.01% | 128500 SH | 11 सितमबर 2026 | दैनिक |
| IWV · iShares Trust | 0.01% | 25737 SH | 11 सितमबर 2026 | दैनिक |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 75392 SH | 19 अगस्त 2026 | दैनिक |
| IWN · iShares Trust | · | 760375 SH | 11 सितमबर 2026 | दैनिक |
| ISCB · iShares Trust | · | 4191 SH | 11 सितमबर 2026 | दैनिक |
| ISCV · iShares Trust | · | 20690 SH | 11 सितमबर 2026 | दैनिक |
| SMLF · iShares Trust | · | 58519 SH | 11 सितमबर 2026 | दैनिक |
CRSP विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
रेटिंग · 28 विश्लेषक
खरीदें
मध्यिका लक्ष्य
$80.00
+44.3%
6 21.4%
मजबूत खरीद
11 39.3%
खरीदें
11 39.3%
होल्ड
0 0.0%
बेचें
0 0.0%
मजबूत बिक्री
12-महीने का मूल्य लक्ष्य
18 विश्लेषक · 2026-10-03माध्य लक्ष्य $87.56 +58.0%
अभी
वर्तमान मूल्य $55.43
निम्न$44.00
माध्य$87.56
उच्च$291.00
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Nasdaq · 3 weeks, 1 day पहले
Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
Yahoo Finance · 2 months, 2 weeks पहले
2 Beaten-Down Stocks With Massive Upside Potential
Nasdaq · 2 months, 3 weeks पहले
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Yahoo Finance · 3 months, 3 weeks पहले
CRISPR Therapeutics स्टॉक आश्चर्यजनक रूप से सस्ता है -- यहाँ बताया गया है कि विश्लेषकों को 437% ऊपर की ओर संभावित क्यों दिखता है
Nasdaq · 4 months पहले
मेगा-कैप ग्रोथ लीडरशिप या स्मॉल-कैप ग्रोथ पोटेंशियल? VUG बनाम VBK
Nasdaq · 4 months पहले
1 टॉप वॉल स्ट्रीट विश्लेषक का मानना है कि सीआरआईएसपी थेरेप्यूटिक्स दोगुने से अधिक हो सकता है। क्या आपको हाथ से स्टॉक खरीदना चाहिए?
Yahoo Finance · 4 months, 2 weeks पहले
ARKK, CRSP, TEM, HOOD में उल्लेखनीय ईटीएफ बहिर्वाह का पता चला
Nasdaq · 5 months, 2 weeks पहले
यह बायोटेक पाइपलाइन अपने पूरे चिकित्सीय क्षेत्र को फिर से परिभाषित कर सकती है
Nasdaq · 5 months, 3 weeks पहले
कैथी वुड डिस्काउंट हंटिंग पर: उन्होंने अभी-अभी 2 स्टॉक खरीदे हैं
Nasdaq · 5 months, 3 weeks पहले
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
स्रोत: SEC 10-Q अग 3, 2026 को फाइल किया गया